Kalytera Therapeutics, Inc.

40 articles about Kalytera Therapeutics, Inc.

• 

  Biopharma Update on the Novel Coronavirus: June 10

  6/10/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
• 

  Clinical Catch-up for August 19-23

  8/26/2019

  Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.

• Kalytera Provides Update on Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

  12/20/2018

  No Patients Have Developed Grades 3-4 Acute GVHD While Receiving CBD Treatment

• Kalytera to Enter Medical Cannabis Market With Focus on Treatment of Psoriasis and Menstrual Cramps

  7/19/2018

  Kalytera Therapeutics, Inc. announced that it has entered into an agreement with Beetlebung Pharma, Ltd. ("BPL") for an option to acquire all rights to medical cannabis products in development by BPL for the treatment of both dermatologic diseases and women's health.

• Kalytera Announces Issuance of Second Patent Covering the Use of CBD in Graft Versus Host Disease

  5/2/2018

  Kalytera Therapeutics, Inc. announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 9,956,182.

• Kalytera Reports 2017 Financial Results

  5/1/2018

  Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the year-ended December 31, 2017. (All dollars U.S. unless otherwise noted.)

• Kalytera Announces Issuance of Patent Covering the Use of CBD for the Treatment of Severe and Refractory Graft Versus Host Disease

  4/19/2018

  Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 9,889,100 B2 with claims covering the use of cannabidiol ("CBD") for the treatment of severe and refractory graft versus host disease ("GVHD")

• Kalytera Terminates Pre-Clinical Programs in Bone Disease

  4/13/2018

  Company to Focus Resources on GVHD and Pain Programs

• Kalytera Announces Grant of Stock Options

  1/31/2018

  The stock options have an exercise price of $0.38 per common share and expire ten years from the date of grant.

• Kalytera Announces Issuance of Shares Under Services Agreement With The Salzman Group of Israel

  1/26/2018

  Under the deal, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease.

• Kalytera Announces Settlement of Debt Transaction

  1/12/2018

  The debt owing is in the amount of US$76,000 (or C$94,969.60 based on the daily average exchange rate for January 10, 2018 published by the Bank of Canada).

• Kalytera Announces Approval of Shares for Services and Settlement of Debt Transaction With The Salzman Group of Israel

  12/27/2017

  Under the deal, the TSXV has also approved, and the Company has completed, a settlement of certain debts previously owing through the issuance of Common Shares to The Salzman Group.

• Kalytera Announces Initiation of Phase II Clinical Study in Prevention of Graft Versus Host Disease and Agreement With The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team

  12/7/2017

  The Phase 2 study is designed to assess the pharmacokinetic and safety profile of multiple doses of CBD for the prevention of GVHD.

• Kalytera Confirms No Material Change in Operations

  12/6/2017

  The company confirms that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

• Kalytera Announces Second U.S. Patent for Prevention and Treatment of Graft Versus Host Disease

  11/27/2017

  Kalytera’s Phase 2 study is expected to enroll 36 patients following allogeneic hematopoietic cell transplantation ("HCT"), commonly referred to as bone marrow transplantation.

• Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Disease

  11/15/2017

  Securing a patent for this proprietary technology represents an important step forward for the Company in its work focused on the treatment of this serious and life-threatening disease.

• Kalytera Announces Robert Farrell, J.D. As CEO; Additional Board And Management Changes

  10/11/2017

• Kalytera Receives IRB Approval For Proposed Phase II Study Evaluating CBD In The Prevention Of Graft Versus Host Disease

  9/7/2017

• Kalytera Reports Second Quarter 2017 Financial Results

  8/31/2017

• Kalytera Submits Phase II Study Protocol To Irbs For Cannabidiol In The Prevention Of Graft Versus Host Disease

  8/14/2017